CTSG and rheumatoid arthritis: We now report that brensocatib downregulates the activity of the main pathophysiologically relevant DPP-1 substrates (e.g. NE, CatG, PR3) in two animal models of RA, and describe the outcomes of brensocatib treatment in these disease models.